Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo
March 23rd 2022Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.